[ad_2]
NEW YORK, Nov. 7, 2022 /PRNewswire/ — JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, recognizes this year’s National Diabetes Awareness Month (NDAM) by celebrating the progress made and the work to come with its new “FORWARD” campaign.
“For more than 50 years, JDRF has been at the forefront of research progress, shepherding new advancements to better the lives of those impacted by type 1 diabetes,” said Aaron Kowalski, Ph.D., JDRF CEO. “This National Diabetes Awareness Month, as we celebrate how far we have come, we recognize the path forward is still being defined and will ultimately lead to breakthroughs to cure, prevent and treat type 1 diabetes and its complications.”
The “FORWARD” campaign will inspire the T1D community and others to share their story, educate those around them, and demonstrate the impact of research on improving lives and eliminating type 1 diabetes for good. For members of JDRF and the broader T1D community, #ForwardAs1 is a reminder of the vision and mission to cure, prevent and treat T1D and its complications.
JDRF also recognized NDAM by hosting One Conference, November 1 – 3 in Washington D.C., an annual event for JDRF volunteers and leaders. The event honored five outstanding volunteer community members whose local and national impact has helped to push JDRF’s mission forward. Award recipients included:
During One Conference, JDRF announced the establishment of the Kellogg Family Research Award. This award provides crucial support to clinician-scientists at the start of their careers in T1D-related clinical investigation. This is research at the nexus of innovation and patient care. The grant is named for JDRF supporters Bill and Bonnie Kellogg. Bill and Bonnie have supported JDRF’s research efforts since 1996, when their son Jeff, then age 23, was diagnosed with T1D.
To learn more about the JDRF FORWARD campaign and other initiatives, please visit https://www.jdrf.org/NDAM/.
JDRF’s mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.5 billion
T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all, leading to long-term complications which can include highs and lows in blood sugar; damage to the kidneys, eyes, nerves and heart; and even death if left untreated. It is one of the fastest-growing chronic health conditions. Many believe T1D is only diagnosed in childhood and early puberty, but diagnosis in adulthood is on the rise, and accounts for nearly 50% of all T1D diagnoses. The onset is sudden and nothing can be done to prevent it yet—it is not related to diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D.
SOURCE JDRF
Source link
[ad_2]
The content is by PR Newswire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.
[ad_2]
[ad_1] Nørresundby, 26 April 2024Announcement no. 23/2024 The Board of Directors of RTX has, cf. company announcement no. 20/2023 dated…
[ad_1] Gyroscope Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033 The Business Research Company's Gyroscope Global…
[ad_1] ODISHA, India, and LOS ANGELES, Calif., April 25, 2024 (SEND2PRESS NEWSWIRE) — In the 1880s, to call attention to…
In support of Hong Kong's new mega tourism and commerce drive, Alipay+ now enables users of 14 leading overseas mobile…
[ad_2] TOKYO, April 26, 2024 /PRNewswire/ -- KLab Inc. announced that its hit 3D action game Bleach: Brave Souls has…
[ad_1] CALGARY, Alberta, April 24, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of TransAlta Corporation (TSX: TA) (NYSE: TAC)…